Date: 2013-01-28
Type of information: Series A financing round
Company: Avillion (UK)
Investors: Abingworth (UK) Clarus Ventures (USA - CA)
Amount: undisclosed
Funding type: series A financing round
Planned used: This financing round is Avillion\'s initial financing round. This new company is focused on clinical co-development of
therapeutics.Avillion, based in London, UK, is partnering with pharmaceutical and biotechnology companies to co-develop and finance late stage therapeutics. The company will use its clinical development and regulatory expertise to obtain global approvals for a broad range of drugs and biologics.
The management team is led by Lewis Cameron (CEO), who has held senior executive positions in CRO companies,including
Chiltern International, Clearstone and LabCorp. Dr Allison Jeynes-Ellis (CMO) has over 20 years experience running clinical
trials for pharmaceutical companies, including Wyeth and BMS, and has been extensively involved in health technology appraisals across various countries. Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca. John Bradshaw (CFO) provides financial services to life sciences companies and has extensive experience in dealing with complex accounting and finance issues relevant to the pharmaceutical industry.
Others: * On January 28, 2013, Avillion LLP, which focuses on clinical co-development of therapeutics, announced that it has received initial funding from Abingworth LLP and Clarus Ventures.
Therapeutic area:
